



Drug Quantity Management – Per Days Weight Loss – Wegovy® (semaglutide subcutaneous injection)

Table of Contents

National Formulary Medical Necessity	1
Conditions Not Covered.....	2
Background.....	2
References	3
Revision History.....	3

Product Identifier(s)

94942

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

National Formulary Medical Necessity

This Drug Quantity Management program has been developed to manage potential dose escalation of Wegovy. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for the duration noted below.

Drug Quantity Limits

Product	Strength and Form	Maximum Quantity per 365 Days
Wegovy® (semaglutide subcutaneous injection)	0.25 mg/0.5 mL prefilled pen-injector	8 prefilled injectors per 365 days
	0.5 mg/0.5 mL prefilled pen-injector	8 prefilled injectors per 365 days
	1 mg/0.5 mL prefilled pen-injector	8 prefilled injectors per 365 days
	1.7 mg/0.75 mL prefilled pen-injector	8 prefilled injectors per 365 days
	2.4 mg/0.75 mL prefilled pen-injector	4 prefilled injectors per 28 days

Cigna covers quantities as medically necessary when the following criteria are met:

Wegovy 0.25 mg/0.5mL prefilled pen-injector

1. If more than two consecutive doses are missed, and re-initiation of treatment is needed, approve a one-time override for eight additional syringes.
2. No other exceptions are recommended.

Wegovy 0.5 mg/0.5 mL prefilled pen-injector

1. If more than two consecutive doses are missed, and re-initiation of treatment is needed, approve a one-time override for eight additional syringes.
2. No other exceptions are recommended.

Wegovy 1 mg/0.5 mL prefilled pen-injector

1. If more than two consecutive doses are missed, and re-initiation of treatment is needed, approve a one-time override for eight additional syringes.
2. No other exceptions are recommended.

Wegovy 1.7 mg/0.75 mL prefilled pen-injector

1. If more than two consecutive doses are missed, and re-initiation of treatment is needed, approve a one-time override for eight additional syringes.
2. If the individual does not tolerate the maintenance 2.4 mg once weekly dose and the dose needs to be temporarily decreased to 1.7 mg weekly, approve a one-time override for four additional syringes.
Note: After the four additional weeks of 1.7 mg, the dose should be increased to 2.4 mg. If the individual still cannot tolerate the 2.4 mg dose after the temporary dose reduction to 1.7 mg, Wegovy should be discontinued.
3. No other exceptions are recommended.

Wegovy 2.4 mg/0.75 mL prefilled pen-injector

No overrides.

Conditions Not Covered

Any other exception is considered not medically necessary.

Background

Overview

Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for **chronic weight management** in adults with an initial body mass index ≥ 30 kg/m² (obese), or ≥ 27 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes).¹

Dosing

In the prescribing information for Wegovy, a recommended dose escalation schedule of 16 weeks is outlined.¹ If a patient does not tolerate a dose during dose escalation, consider delaying dose escalation for 4 weeks. The maintenance dose of Wegovy is 2.4 mg injected subcutaneously once weekly. If a patient does not tolerate the maintenance 2.4 mg once weekly dose, the dose can be temporarily decreased to 1.7 mg once weekly, for a maximum of 4 weeks. After 4 weeks, increase Wegovy to the maintenance 2.4 mg once weekly dose. Discontinue Wegovy if the patient cannot tolerate the 2.4 mg dose. The recommended Wegovy dose escalation schedule is provided in Table 1.

Wegovy is supplied in prefilled, disposable, single-dose pen-injectors.¹ A quantity of four 0.25 mg, 0.5 mg, 1 mg, and 1.7 mg prefilled pen-injectors will be covered per 365 days. This is enough drug for dose escalation to the maintenance dose. A quantity of four 2.4 mg prefilled pen-injectors will be covered per 28 days. This is enough drug to allow for once weekly maintenance dosing. One-time exceptions for missed doses, re-initiation of treatment, or temporary dose reduction are provided through coverage review.

Table 1. Wegovy Dose Escalation Schedule.¹

Weeks	Weekly Dose	
1 through 4	0.25 mg	Dose Escalation
5 through 8	0.5 mg	
9 through 12	1 mg	
13 through 16	1.7 mg	
Week 17 and onward	2.4 mg	Maintenance Dose

References

1. Wegovy® subcutaneous injection [prescribing information]. Plainsboro, NJ: Novo Nordisk; June 2021.

Revision History

Type of Revision	Summary of Changes	Approval Date
New policy	Reviewed and approved by TAC	06/16/2021
Early Annual Revision	Criteria: For Wegovy 0.25, 0.5, 1, and 1.7 mg strengths, the criterion regarding intolerance during dose titration was reworded to “if the patient requires a delay in dose escalation of 4 additional weeks due to tolerability during dose titration, approve a one-time approval for four additional syringes.” Previously, the criterion only provided an override for a patient who did not tolerate the requested dose. Also for Wegovy 0.25, 0.5, 1, and 1.7 mg strengths, the criterion regarding re-initiation of treatment due to missed doses was revised to allow for a one-time override of four additional syringes regardless of which dosage strength was missed.	02/16/2022
Selected Revision	Quantity Limits: The quantity limits for Wegovy 0.25 mg, 0.5 mg, 1 mg, and 1.7 mg were updated to 8 syringes per 365 days; previously the limit was 4 syringes per 365 days. Criteria: For Wegovy 0.25 mg, 0.5 mg, 1 mg, and 1.7 mg strengths, the exception regarding a one-time override for four additional syringes if needed for tolerability was removed; this is no longer needed since initial quantity limits now provide a total of eight syringes. For the exception regarding an additional one-time override if re-initiation of titration is needed, the quantity was changed from four to eight syringes.	06/22/2022

“Cigna Companies” refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc. and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2022 Cigna.